Rinvoq ER 30 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DR26F5QB8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,686
Award facts
- Contract value 100% obligated
- $14,685.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, valued at $14,685.97 for RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The order is scheduled for completion by November 21, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of inflammatory conditions, reflecting the pharmaceutical supply needs of the Department of Defense medical system.
This delivery order is issued against AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that supports global pharmaceutical supply for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, and serves as a critical vendor for federal medical procurement, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's demonstrated capability to fulfill federal medical supply requirements across multiple therapeutic domains has established it as a key partner in the Department of Defense medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F5QB8?
SPE2DR26F5QB8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26F5QB8 worth?
The government has obligated $14,686 on SPE2DR26F5QB8.
Is contract SPE2DR26F5QB8 an order under another contract?
Yes. SPE2DR26F5QB8 is a delivery order under SPE2DR25D3003, an indefinite delivery contract.
Was contract SPE2DR26F5QB8 competed?
The extent of competition for SPE2DR26F5QB8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award